Second chance: nonconforming CAR T-Cell therapy offered to myeloma patients
NCT ID NCT04771078
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This expanded access program provides a CAR T-cell therapy called ide-cel to people with multiple myeloma whose specially made treatment batch did not meet commercial standards. The goal is to offer a treatment option when no other suitable therapy is available. Participants must be clinically stable and have no other feasible treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.